Business
Publication of Circular &Notice of General Meeting
Publication of Circular &Notice of General Meeting.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \n \n \n 16 December 2022\n \n \n \n \n \n \n \n THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\n \n \n \n \n \n \n \n \n \n THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF SHIELD THERAPEUTICS PLC IN ANY JURISDICTION.\n \n \n \n \n \n \n \n \n \n Shield Therapeutics plc\n \n \n \n \n (\"Shield Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n Publication of Circular and Notice of General Meeting\n \n \n \n \n \n \n \n \n London, UK - 16 December 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company, announces that, further to the announcement on 13 December 2022, confirming the successful completion of the Placing and Subscription, a Circular will shortly be published on the Company's website,\n \n www.shieldtherapeutics.com\n \n , and will be posted to Shareholders later today. The Circular contains the notice convening the General Meeting to be held at 2.00 p.m. on 5 January 2023.\n \n \n \n \n \n In order to provide Qualifying Shareholders with an opportunity to participate in the Transaction, the Company will today make the Open Offer to Qualifying Shareholders on the terms and conditions set out in the Circular. The Open Offer provides all Qualifying Shareholders with the opportunity to subscribe at the Issue Price of 6 pence per share for an aggregate of up to 64,346,927 Open Offer Shares to raise up to approximately £3.9m (before fees and expenses) for the Company, on the basis of:\n \n \n \n \n \n \n 1 Open Offer Share for every 4 Existing Ordinary Shares held as at the Record Date.\n \n \n \n \n \n \n \n \n The Open Offer is conditional on the Placing and the Subscription becoming or being declared unconditional in all respects and not being terminated before Admission. Accordingly...